Sonoma Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. (SNOA) on October 3, 2025. The filing discloses significant executive personnel changes, including an amended employment agreement for the Chief Executive Officer and the announced retirement of the Chief Operating Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and personnel transitions.
Material Changes
- CEO Compensation Update: An amended and restated employment agreement was executed with CEO Amy Trombly effective October 3, 2025. Her base salary is set at $475,000 per annum with a target annual bonus of 50% of base salary.
- COO Departure: Executive Vice President and Chief Operating Officer Bruce Thornton notified the company of his intent to retire effective December 2, 2025. The position of Chief Operating Officer will be eliminated upon his departure.
- Severance and Benefits:
- CEO: Severance for termination without Cause or for Good Reason is paid via regular payroll. In a Change in Control scenario, severance increases to two times annual base salary plus two times the target bonus. COBRA reimbursement is extended to 12 months (24 months in Change in Control). Equity awards remain exercisable for 24 months post-termination.
- COO: Mr. Thornton is eligible for $300,000 in severance contingent on a general release of claims. He receives up to 12 months of COBRA reimbursement. All time-based equity awards vest immediately; performance-based awards remain subject to original terms. Vested equity is exercisable for 18 months post-termination.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of market risks. The primary operational risk noted is the transition of responsibilities following the elimination of the COO role, with Mr. Thornton assisting in the transition over the next two months.
Investor Verification Checklist
- Verify the full text of the Amended and Restated Employment Agreement (Exhibit 10.1) for complete terms regarding "Cause" and "Good Reason."
- Confirm the timeline for the transition of the Chief Operating Officer's duties prior to the December 2, 2025 effective date.
- Review the company's capital structure to assess the impact of the $300,000 contingent severance payment for the departing COO.
- Monitor future filings for the appointment of a successor to the COO role or the redistribution of those duties.